



# Can Stem Cell Therapy be an Effective Therapeutic Option for Complex and Neurological Conditions?

Sophea Lo\*, Raymund Gantioque

Patricia A. Chin School of Nursing, California State University of Los Angeles



\* Corresponding Author email:  
phea0414@gmail.com

## Article History

Received: 06 March 2024

Revised: 20 April 2024

Accepted: 30 April 2024

Published: 16 May 2024

## Student(s)

- Sophea Lo

Academic Year: 2023-2024

Course Level: Master

Course Name: M.Sc. (Advanced Care)

Course year: 2<sup>nd</sup> Year

## Mentor(s)

- Raymund Gantioque

## ABSTRACT

This article explores the feasibility and potential benefits of stem cell therapy as a promising therapeutic intervention for individuals facing severe behavioral and cognitive impairments, targeting underlying neurological mechanisms to offer potential symptom improvement and function restoration, thereby enhancing the quality of life for patients and potentially alleviating stress and burnout among caregivers. The aims of the study include investigating the efficacy of stem cell therapy in addressing these impairments and evaluating its potential to alleviate caregiver burden. Through a comprehensive review of existing literature, clinical trials, and studies, this research synthesizes the mechanisms of stem cell therapy, potential applications, clinical trial outcomes, caregiver experiences, and economic implications. The methods employed involve analyzing diverse data sources to provide a holistic understanding of the possibilities and challenges associated with stem cell therapy. Key outcomes of the study include highlighting promising results from clinical trials targeting conditions such as autism spectrum disorder, Parkinson's disease, and Crohn's disease, which underscore the transformative potential of stem cell therapy in patient care. Additionally, economic implications suggest potential reductions in healthcare costs and alleviation of financial strain on individuals, families, and healthcare providers. Stem cell therapy represents a paradigm shift in healthcare, promising to redefine treatment approaches and alleviate broader societal burdens associated with complex neurological conditions. The relevance of the study lies in emphasizing the need for continued research, ethical considerations, and multidisciplinary collaboration to ensure the safe and effective integration of stem cell therapy into clinical practice, ultimately offering new hope and improved care for patients, caregivers, and healthcare systems worldwide.

**Keywords:** Stem Cell Therapy, Neurological Conditions, Healthcare Cost



## 1 Introduction

Stem cell therapy represents a compelling course in modern healthcare research for complex [1] and neurological conditions [2]. With the potential to address a spectrum of debilitating conditions, including autoimmune and neurological disorders, stem cell therapy offers a multifaceted approach to improving patient outcomes and addressing broader healthcare challenges [3], [4], [5]. This inquiry examines the feasibility and potential benefits of utilizing stem cells as a therapeutic intervention for complex illnesses and disorders. Central to this review is exploring how stem cells may enhance the quality-of-life [6] for individuals grappling with severe conditions such as behavioral issues and cognitive impairments [7]. By targeting underlying neurological mechanisms, stem cell therapy holds promise in improving symptoms and restoring functions [2], [8] thereby offering new hope for patients and their families. Further, the exploration of stem cell therapy extends beyond the realms of patient care to encompass the well-being of caregivers [9], [10]. The physical, emotional, and financial toll incurred by caregivers of individuals with complex and neurological conditions is substantial [11], [12], often leading to burnout and diminished quality of life. By alleviating caregiver stress and burden, stem cell therapy could potentially enhance the overall support network for patients and caregivers alike [11], fostering a more sustainable and compassionate healthcare ecosystem. Moreover, the economic implications of stem cell therapy are significant, particularly concerning healthcare costs for patients who require institutionalized care and are dependent on extensive support services [10], [11]. By potentially reducing hospitalizations, minimizing the need for long-term care facilities, and mitigating the burden on healthcare systems, stem cell therapy offers the prospect of not only improving patient outcomes [13] but also alleviating financial strain on individuals, families, and healthcare providers [11]. In essence, the exploration of stem cell therapy for complex and neurological conditions represents a paradigm shift in healthcare [14], with the potential to redefine treatment approaches, enhance quality of life, and alleviate the broader societal burdens associated with these conditions [9]. Through a comprehensive examination of its potential benefits and challenges, this inquiry seeks to highlight the transformative possibilities of stem cell therapy and its implications for patients, caregivers, and healthcare systems worldwide [10], [11].

## 2 Stem Cell Therapy

Stem cell therapy works by harnessing the regenerative and differentiation capabilities of stem cells to repair damaged tissues [15], replace diseased cells, and restore normal function in the body [16], [17]. Stem cells can be derived from various sources, including embryonic stem cells derived from mesenchymal stem cells (Es MSCs) [18], and Human induced pluripotent stem cell (iPSC) [19] generated from reprogrammed adult cells.

Stem cells have unique capabilities and diverse applications in regenerative medicine. Mesenchymal Stem Cells (MSCs) are multipotent cells derived from various tissues, capable of forming bone, cartilage, and fat cells [6]. Hematopoietic Stem Cells reside in the bone marrow and support all blood cell types [4], [13]. Adipose Stem Cells are obtained from fat tissue and can differentiate into fat cells [16] and other cell types. Induced Pluripotent Stem Cells (iPSCs) are artificially created from adult cells and exhibit embryonic stem cell-like properties, while Embryonic Stem Cells are derived from early-stage embryos [20] and possess the ability to differentiate into any cell type [13], [15], [18]. Each type of stem cell offers unique potential for therapeutic interventions and medical advancements.

Stem cells are administered to patients through various delivery methods, including injections, infusions, or surgical implantation. Administration of therapy is dependent on the target tissue or organ and the specific medical condition being treated. Once transplanted, stem cells have the potential to integrate into the existing tissues, replace damaged or dysfunctional cells [21], and promote tissue regeneration and repair through various mechanisms, including cell-to-cell signaling [22], immunomodulation, and secretion of trophic factors [17]. Patients undergoing stem cell therapy are typically monitored closely to assess treatment efficacy, safety, and any potential adverse effects. Follow-up evaluations may include clinical assessments,

imaging studies, and laboratory tests to track the progression of the disease and the response to treatment over time [3]. It is important to note that the success of stem cell therapy depends on several factors, including the type and source of stem cells used, the specific characteristics of the target tissue or organ, the stage and severity of the disease, and individual patient factors such as age, overall health, and immune status [2], [6], [23]. Subsequently, stem cell therapy is an evolving therapeutic, and ongoing research is essential to further advance its safety, efficacy, and applicability across a wide range of medical conditions [3], [4], [19].

### **3 Examples of Complex Diseases and How Stem Cells Can be Used:**

#### **3.1 Autism Spectrum Disorder (ASD)**

Autism Spectrum Disorder is a developmental condition that impacts the perception and interaction of individuals within their environment [4], [24]. It is characterized by a spectrum of symptoms, resulting in significant variability among affected individuals. Key features of ASD encompass challenges related to social communication, including difficulties in comprehending, utilizing verbal and nonverbal cues, initiating and maintaining conversations, and grasping social subtleties [6]. Repetitive behaviors, intense narrow interests, and heightened or diminished sensory sensitivities are also commonly observed [16]. Children with ASD often struggle with adapting to changes in routines, and they may face challenges in understanding the perspectives of others. In the US, 1 in 36 children have autism, up from the previous rate of 1 in 44 [1]. 1 in 45 adults in the U.S. have autism [25]. In the U.S., about 4 in 100 boys and 1 in 100 girls have autism [26]. Boys are nearly 4 times more likely to be diagnosed with autism than girls [2].

Stem cell therapy for ASD is based on the potential to modulate inflammation, promote neurogenesis, and improve synaptic connectivity in the brain [23]. Since ASD is a neurodevelopmental disorder characterized by impaired communication and social interaction, as well as repetitive behaviors, [13] literature showed that stem cell therapy could help address some of these deficits. While there have been a few clinical trials investigating stem cell therapy for ASD, the results have been mixed, and the overall evidence is still limited. Some trials have reported improvements in behavioral symptoms and cognitive function following stem cell treatment [20], while others have not shown significant benefits [9]. Additionally, many of these trials have been small-scale and lacked rigorous study designs, making it challenging to draw definitive conclusions about the effectiveness of stem cell therapy for ASD. For example, [4] conducted a study on a 25-year-old autistic adult using autologous bone marrow-derived mononuclear cells (BMMNCs), reporting improvements in various areas such as concentration, attention, and social interactions. [18] investigated the safety and efficacy of combined transplantation of cord blood-derived mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in children with autism, reporting significant improvements in behavior and cognition [21]. Another study evaluated the safety and effectiveness of fetal stem cell (FSC) transplantation in autistic children, showing improvements in sociability and cognitive ability without adverse effects [12], [21]. Lastly, the results of a clinical trial on autologous umbilical cord blood (AUCB) transplantation in ASD children showed minimal evidence of clinical effectiveness [6], with varying dosages and inconsistent results compared to previous studies. Studies have demonstrated that certain types of stem cells, such as mesenchymal stem cells (MSCs) derived from bone marrow or umbilical cord tissue, may have immunomodulatory and neuroprotective effects that could potentially benefit individuals with ASD [6], [7], [27].

Currently, there are several challenges and considerations associated with stem cell therapy for ASD. These include variability in patient responses, potential safety concerns, ethical considerations [5], and the need for standardized treatment protocols [6], [8]. Additionally, ASD is a complex and heterogeneous disorder, and not all individuals may respond similarly to stem cell therapy. Despite the current limitations, research in the field of stem cell therapy for ASD continues to advance [6], [7], [14], [17]. Ongoing studies are exploring different stem cell sources, administration routes, and treatment modalities to optimize therapeutic outcomes. Additionally, further research is needed to better understand the underlying

mechanisms of ASD [24] and identify biomarkers [15] that could help predict treatment response and guide personalized therapy approaches.

Stem cell therapy holds considerable promise for alleviating symptoms associated with Autism Spectrum Disorder (ASD) by targeting various underlying mechanisms. These include neuroregeneration, where stem cells replace damaged neural cells and potentially improve cognitive function and behavior. Stem cells also possess anti-inflammatory properties, which help modulate neuroinflammation, a factor increasingly implicated in ASD. Additionally, stem cells enhance neuroplasticity, promoting the formation of new neural connections and aiding in learning and adaptation. Their secretion of neurotrophic factors supports neuronal growth and repair, further benefiting individuals with ASD. Moreover, stem cells may indirectly influence behavioral symptoms by regulating gastrointestinal function, addressing common gastrointestinal issues in ASD. This comprehensive approach to addressing multiple aspects of ASD pathology is a promising avenue worth exploring further. Ongoing research suggests that stem cell therapy offers significant benefits for individuals with ASD, although further investigation is needed to confirm its safety and efficacy.

### 3.2 Parkinson's Disease

Parkinson's Disease is a neurological disorder that slowly affects the body's nervous system [15]. Symptoms may begin slowly with tremors in one hand, rigidity, slow movement, [23] and impaired balance. The occurrence of Parkinson's disease (PD) based on healthcare usage ranges from 5 to more than 35 new cases per 100,000 individuals annually [2]. The incidence of PD escalates significantly by 5 to 10 times from the sixth to the ninth decades of life [27]. Moreover, PD prevalence rises with age, as demonstrated in a meta-analysis of four North American populations [2], [15] where it surged from under 1% among individuals aged 45–54 years to 4% among men and 2% among women aged 85 or older [2].

Stem cell treatment for Parkinson's may offer therapeutic benefits primarily through their natural secretion of anti-inflammatory signals [15] and other molecules crucial for cell survival, commonly referred to as bystander effects [2]. For instance, mesenchymal stem cells (MSCs) exhibit anti-inflammatory [28], anti-apoptotic, and regenerative properties. Both ESC-MSCs and iPSC-MSCs can impede the proliferation of lymphocytes and natural killer cells, suggesting potential in immunoregulatory cell-based therapies [9]. Exosomes hold promise in treating Parkinson's disease (PD). Exosomes derived from MSCs possess anti-inflammatory [14], antioxidant, and neurotrophic characteristics [27], ultimately promoting functional recovery in PD animal models [23].

One appealing aspect of stem cell treatment is their adaptability before implantation, allowing the enhancement of anti-inflammatory actions [22]. An interesting pathway involves interferon- $\gamma$  signaling through the gene LRRK2 [15]. The LRRK2 G2019S mutation is the most prevalent genetic anomaly linked to inherited PD [19]. In PD patient-derived iPSCs carrying the LRRK2 G2019S mutation [27], IFN- $\gamma$  signaling exacerbates immunomodulated neuronal damage [14]. Initially activated by IFN- $\gamma$ , MSCs subsequently exhibit anti-inflammatory properties. Consequently, MSCs may effectively regulate this pathological signaling [14].

In terms of clinical trials, several have been investigated on fetal ventral mesencephalon (FVM) grafts for Parkinson's disease (PD) showing mixed results [5], [20], [21]. Upon promising trials in Sweden, the US led similar trials which led to minimal clinical benefits due to issues related to insufficient fetal tissue, the presence of serotonergic neurons, and inadequate immunosuppression [7]. However, these findings generated valuable understanding into effective cell-based therapy design. More recent research has focused on alternative cell sources, including carotid body cells [27], retinal pigment [28] epithelial cells [9], and porcine mesencephalon tissue, but none have produced significant benefits for PD patients [20]. Despite setbacks, these trials have demonstrated the possibility of neural grafting for PD patients, prompting additional discovery in scalable, sustainable sources of dopaminergic neurons, guiding more investigative use for stem cells as a promising option for regenerative medicine [14].

The information provided underscores the significant impact of Parkinson's disease (PD) on individuals, with symptoms gradually affecting the nervous system, leading to tremors, slow movement, and stiffness. The rising incidence of PD with age, especially in the elderly population, highlights the pressing need for effective treatments. Stem cell therapy emerges as a promising avenue, offering therapeutic benefits through their natural secretion of anti-inflammatory signals and other molecules crucial for cell survival. Stem cells, such as mesenchymal stem cells (MSCs), exhibit anti-inflammatory, anti-apoptotic, and regenerative properties, potentially modulating immune responses and promoting tissue repair. Advancements in healthcare utilizing stem cell therapy to address the complex mechanisms of PD offer hope that may improve the quality of life for patients immensely.

### **3.3 Rheumatoid Arthritis (RA)**

Rheumatoid Arthritis is a persistent autoimmune condition marked by joint inflammation, resulting in pain, swelling, stiffness, and eventual damage to the joints [29]. Conventional treatments for RA involve the use of medications to alleviate inflammation and address symptoms. Nevertheless, current research has explored the potential utilization of stem cell therapy as a groundbreaking approach to address and manage RA. In the United States, around 1.3 million adults have RA, representing 0.6% to 1% of the adult population, with approximately 35% experiencing work disability associated with the condition [29].

Stem cell therapy for rheumatoid arthritis is based on the potential to help control immune response, reduce inflammation, and promote tissue repair and regeneration [8]. Mesenchymal stem cells (MSCs)-derived exosomes show promise in RA treatment by reducing joint inflammation, bone destruction, and immune-mediated damage. RA is characterized by an imbalance in T cell subpopulations [29], preclinical studies in animal models have shown promising results by reducing inflammation, soothing joint damage, and improving joint function [28]. In clinical trials involving patients, MSC therapy has been associated with improvements in disease activity, reduction in joint pain, and enhanced quality of life [15], [22]. However, the results have been variable across studies, and further research is needed to determine the optimal dosing, timing, and administration route of stem cell therapy for rheumatoid arthritis [28]. Although promising, safety considerations and risks associated with stem cell therapy for RA include infection, immune reactions [7], tumor formation [14], and adverse effects related to the transplantation procedure. As such, ensuring safety and ethical conduct of clinical trials is essential in evaluating risks and benefits of stem cell therapy for rheumatoid arthritis. Despite challenges and uncertainties, research in stem cell therapy for RA continues to advance. Ongoing studies are exploring novel approaches, such as using genetically modified stem cells or combination therapies to enhance the therapeutic efficacy and safety of stem cell-based treatments [28], [29]. Additionally, further research is needed to better understand the underlying mechanisms of rheumatoid arthritis and identify patient-specific factors that may influence treatment outcomes.

The significance of stem cell therapy for rheumatoid arthritis (RA) lies in its potential to revolutionize how we address and manage this persistent autoimmune condition. With conventional treatments often focusing on symptom management, stem cell therapy offers a groundbreaking approach by targeting the underlying mechanisms of RA. By controlling immune responses, reducing inflammation, and promoting tissue repair and regeneration, stem cell therapy holds promise in alleviating joint inflammation, preventing bone destruction, and mitigating immune-mediated damage. Mesenchymal stem cells (MSCs)-derived exosomes, in particular, show considerable potential in preclinical studies and clinical trials, demonstrating improvements in disease activity, joint pain reduction, and enhanced quality of life for patients. Despite variable results across studies and safety considerations, the ongoing advancements in stem cell research for RA, including exploring novel approaches and understanding patient-specific factors, underscore the immense potential of this therapy. To continue improving healthcare outcomes, stem cell therapy offers a great opportunity to address the complexities of RA and enhance the lives of millions affected by this condition.

#### **4 Optimal Time to Apply Stem Cell Therapy**

The application of stem cell therapy is dependent on several factors, including the specific disorder, the stage of the disease, the patient's overall health, and the goals of therapy [30]. In some cases, it may be more effective to administer stem cell therapy earlier in the course of the disease, especially if the goal is to slow or halt disease progression [18], [21], [25]. For progressive neurodegenerative disorders like Parkinson's disease, intervening early may help preserve cognitive function or delay the onset of symptoms. In a recent clinical trial, patients diagnosed with Parkinson's disease, regardless of the duration or stage of the disease [20], [21], [23], were eligible to take part in a treatment study if they could provide adipose tissue for the cultivation of ADSCs and were able to visit the hospital to receive the ADSCs.

In many cases, stem cell therapy is not considered a first-line therapeutic due to limited research and FDA approvals [4], [13]. The feasibility and safety of stem cell therapy may also vary depending on the specific disorder and the stage of the disease. Generally, consideration of stem cell therapy may be more conducive when patients have fewer health complications [1], [11], [21] or are in better well-being. As many stem cell trials for neurological and complex conditions are still experimental, interested candidates should work closely with their providers to identify personal goals and preferences and ensure trials are completed by reputable research institutions [13], [16], [19].

Starting stem cell therapy sooner rather than later is crucial for several reasons. Firstly, the effectiveness of stem cell therapy can be influenced by the stage of the disease. Administering therapy earlier in the disease course may be more effective in slowing or halting disease progression, as seen in neurodegenerative disorders like Parkinson's disease. Secondly, early intervention may help preserve cognitive function and delay the onset of symptoms, highlighting the importance of initiating treatment promptly. Additionally, as stem cell therapy is still considered experimental for many conditions, starting sooner allows patients to access potential benefits while ensuring their eligibility for clinical trials. Furthermore, considering stem cell therapy when patients have fewer health complications or are in better well-being increases the likelihood of successful outcomes. Therefore, beginning stem cell therapy at an early stage offers the best chance for optimizing treatment efficacy and improving patient outcomes.

#### **5 Effective Diagnosis and Interventions to Support Quality of Life**

For healthcare providers, accurately diagnosing and providing the most appropriate therapeutics plays a pivotal role in potentially improving a patient's quality of life, and presumably, life expectancy for individuals facing health challenges [3], [8], [9]. In many cases, a correct diagnosis establishes the foundation of effective treatment. As such, healthcare professional societies have also begun to develop appropriate use or appropriateness criteria as a way of synthesizing the available scientific literature and expert opinion to inform patient-specific decision making [23], [27] precisely identifying the specific condition or disease a patient is facing, providers are able to tailor treatment plans to address the underlying causes and symptoms accurately. This can lead to more focused and targeted interventions, reducing the risk of unnecessary treatments, complications, and delays in care. Early diagnosis allows for prompt initiation of appropriate therapies [18], [21], [24], which can help prevent disease progression, manage symptoms effectively, and minimize long-term complications. Timely intervention is particularly critical for conditions with progressive or degenerative nature [22], where early treatment can significantly impact outcomes and preserve overall health and function [19]. Providing the right therapeutics ensures that patients receive the most effective and evidence-based interventions available for their specific condition. Tailored treatment approaches consider factors such as disease severity, individual patient characteristics, comorbidities, and treatment goals. This personalized approach maximizes therapeutic benefits while minimizing adverse effects and treatment-related burdens [11], [12]. Targeted therapies can alleviate symptoms, improve functional status, and enhance overall well-being, leading to a better quality of life for patients. By addressing symptoms such as pain, fatigue, cognitive impairment, and emotional distress, appropriate therapeutics enable individuals to maintain independence, engage in daily activities, and participate more fully in social

---

and recreational pursuits [2], [3], [4]. Subsequently, effective diagnosis and therapeutics contribute to better health outcomes, including reduced morbidity and mortality rates, decreased hospitalizations, and improved disease control and remission rates. By optimizing health outcomes, individuals can enjoy a higher quality of life, increased productivity, and a greater sense of overall satisfaction and well-being. By managing underlying health conditions, preventing disease complications, and promoting healthy lifestyle behaviors, appropriate diagnosis, and therapeutics can extend life expectancy. Early detection and treatment of complex diseases and neurological disorders can significantly improve long-term survival rates and overall prognosis [16], [18], [21].

## **6 Caregiver Burden**

Caregiver burden, also known as caretaker stress, refers to the physical [9], emotional, and psychological strain experienced by individuals responsible for providing care and support to loved ones with chronic illnesses, disabilities, or age-related conditions [11]. Caretaker stress encompasses a range of challenges faced by caregivers that may include emotional strain, physical demands, social isolation, financial pressure, and health risks. For example, as Parkinson's disease advances, patients undergo a notable deterioration in their quality-of-life [14], leading to considerable financial and emotional strains for both families and society as a whole, [27]. A study conducted in Malaysia included caretakers 18 years or older over a three-month period resulted in burnout prevalence of 8.3%, with personal burnout affecting 32.5%, client-related burnout 17.5%, and work-related burnout 4.6% of caretakers [11]. Common stressors included performance pressure, work-family conflict, and poor job prospects. Family stressors, types of neurological illness in children, and household size were associated with burnout in caretakers [9].

As caregiver stress affects individuals across all age groups and demographics, it is particularly prevalent among middle-aged adults and seniors [8], [11]. Studies indicate that caregivers are at higher risk for depression, anxiety, chronic health conditions, and compromised immune function compared to non-caregivers [8], [9], [11]. Caregiver stress can have significant economic implications, with caregivers in the United States collectively spending billions of dollars annually on out-of-pocket expenses related to caregiving duties. Research suggests that caregivers often neglect their own health and well-being, with many reporting high levels of stress, sleep disturbances, and poor self-care practices [9]. The COVID-19 pandemic has exacerbated caregiver stress, leading to increased levels of isolation, financial strain, and uncertainty about accessing essential resources and support services [11], [12].

Caregiver stress can have significant economic implications and may lead to neglect of their own health and well-being, including poor self-care practices and sleep disturbances. By improving the quality of life and health outcomes of patients, caregivers can experience reduced emotional strain, financial pressure, and overall burden, leading to better mental and physical health for themselves. Therefore, tackling health issues not only benefits the patients but also plays a vital role in supporting the well-being of caregivers, ultimately creating a healthier and more sustainable caregiving environment.

## **7 Healthcare Costs for Patients with Neurological Conditions**

Healthcare costs for treating patients with complex and neurological conditions represent a significant economic burden globally [11], [27]. Treatment costs for these types of conditions may encompass various expenses, which includes diagnostic tests, procedures, medications for symptom management [23] and disease modification [14], hospitalizations and inpatient care, outpatient visits to neurologists, specialists [24], and therapists, rehabilitation and physical therapy services, assistive devices and home modifications [14], long-term care and support services for patients with severe disabilities [27]. The economic burden of neurological disorders in the United States exceeded \$800 billion annually, encompassing direct medical costs [27], indirect costs related to lost productivity, and intangible costs associated with diminished quality of life [16].

Additionally, individuals diagnosed with autism spectrum disorder (ASD) are at a greater likelihood of utilizing healthcare when compared to their counterparts without disabilities, which imposes high medical

costs to families and health systems [16]. Multiple studies discovered that adolescents with ASD experienced a higher percentage of inpatient (3% vs 1%) [16], [18] and outpatient (5% vs 2%) [16] hospitalizations compared to their counterparts without ASD. As a means to potentially reduce healthcare utilization costs, researchers must continue to conduct trials with urgency to form standardized treatment methods [21], [31] and advance treatment outcomes to alleviate financial expenses for autism [16].

Reducing healthcare costs and increasing participation in stem cell research are imperative for several reasons. Firstly, the economic burden of treating complex and neurological conditions, such as Parkinson's disease and autism spectrum disorder (ASD), is substantial, with costs exceeding billions annually. These expenses encompass various medical services, including diagnostic tests, procedures, medications, hospitalizations, and long-term care, contributing to the financial strain on individuals, families, and healthcare systems globally. Stem cell therapy holds promise as a potential avenue for mitigating these costs by offering more effective and efficient treatment options. By advancing stem cell research and developing standardized treatment methods, we can potentially reduce healthcare utilization costs associated with managing these conditions. Additionally, increasing participation in stem cell research is crucial for accelerating the development and implementation of innovative therapies that could alleviate financial burdens on patients and healthcare systems. Moreover, stem cell research has the potential to improve treatment outcomes and quality of life for individuals with complex and neurological conditions, thereby reducing indirect costs related to lost productivity and intangible costs associated with diminished quality of life. Therefore, by reducing healthcare costs and fostering greater participation in stem cell research, healthcare solutions may become more sustainable and accessible for individuals affected by these challenging conditions.

## **8 Conclusion**

Further research is imperative to fully grasp the potential of stem cell therapy in healthcare applications. This innovative approach holds significant promise in improving patient outcomes and addressing complex healthcare challenges. Particularly noteworthy is its capacity to enhance the quality of life for individuals grappling with behavioral and cognitive impairments, hallmarks of various neurological disorders. By targeting underlying neurological mechanisms, stem cell therapy offers hope for symptom alleviation and cognitive function enhancement, thereby instilling renewed optimism among patients and their families. Moreover, the impact of stem cell therapy extends beyond patient care to alleviate the substantial toll experienced by caregivers, including physical, emotional, and financial burdens. By potentially easing caregiver stress and burnout, stem cell therapy can enhance the overall support network for patients and caregivers, fostering a more sustainable and compassionate healthcare ecosystem. The economic implications are equally significant, with the potential to reduce healthcare costs associated with institutionalized care and extensive support services. Stem cell therapy offers the prospect of minimizing hospitalizations, long-term care needs, and alleviating the burden on healthcare systems, ultimately improving patient outcomes while relieving financial strain on individuals, families, and healthcare providers. This exploration of stem cell therapy represents a transformative shift in healthcare, promising to redefine treatment paradigms, enhance quality of life, and alleviate broader societal burdens. Continued rigorous research, ethical considerations, and multidisciplinary collaboration are essential to ensure the safe and effective integration of stem cell therapy into clinical practice, offering new hope and improved care for patients, caregivers, and healthcare systems worldwide.

## **9 Declarations**

### **9.1 Competing Interests**

There is no potential conflict of interest in this publication.

### **9.2 Publisher's Note**

AIJR remains neutral with regard to jurisdictional claims in published institutional affiliations.

---



## How to Cite this Article:

S. Lo and R. Gantioque, "Can Stem Cell Therapy be an Effective Therapeutic Option for Complex and Neurological Conditions?," *Adv. J. Grad. Res.*, vol. 15, no. 1, pp. 12–21, May 2024. <https://doi.org/10.21467/ajgr.15.1.12-21>

## References

- [1] M. J. Maenner *et al.*, "Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020," *MMWR. Surveillance Summaries*, vol. 72, no. 2, 2023, doi: 10.15585/MMWR.SS7202A1.
- [2] D. K. Simon, C. M. Tanner, and P. Brundin, "Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology," *Clin Geriatr Med*, vol. 36, no. 1, pp. 1–12, Feb. 2020, doi: 10.1016/j.cger.2019.08.002.
- [3] N. Sharifzadeh *et al.*, "Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial," *Asia-Pacific Psychiatry*, vol. 13, no. 2, p. e12445, Jun. 2021, doi: 10.1111/APPY.12445.
- [4] A. K. Sharma *et al.*, "Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study," *Am J Stem Cells*, vol. 9, no. 5, p. 89, 2020.
- [5] D. Siniscalco, S. Kannan, N. Semprún-Hernández, A. A. Eshraghi, A. L. Brigida, and N. Antonucci, "Stem cell therapy in autism: recent insights," *Stem Cells Cloning*, vol. 11, pp. 55–67, Oct. 2018, doi: 10.2147/SCCAA.S155410.
- [6] M. Tegtmeyer and R. Nehme, "Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches," *J Mol Biol*, vol. 434, no. 3, p. 167221, Feb. 2022, doi: 10.1016/J.JMB.2021.167221.
- [7] G. Teskey *et al.*, "Intestinal permeability correlates with behavioural severity in very young children with ASD: A preliminary study," *J Neuroimmunol*, vol. 357, p. 577607, Aug. 2021, doi: 10.1016/J.JNEUROIM.2021.577607.
- [8] N. S. L. Yeo-Teh and B. L. Tang, "Moral obligations in conducting stem cell-based therapy trials for autism spectrum disorder," *J Med Ethics*, vol. 48, no. 5, pp. 343–348, May 2022, doi: 10.1136/MEDETHICS-2020-107106.
- [9] M. Yıldız, Y. Demir, A. Kırçalı, and A. Incedere, "Caregiver Burden in Schizophrenia and Autism Spectrum Disorders: A Comparative Study," *Psychiatry Investig*, vol. 18, no. 12, pp. 1180–1187, Dec. 2021, doi: 10.30773/PI.2021.0165.
- [10] S. H. Zuvekas, S. D. Grosse, T. A. Lavelle, M. J. Maenner, P. Dietz, and X. Ji, "Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003–2015," *J Autism Dev Disord*, vol. 51, no. 8, pp. 2950–2958, Aug. 2021, doi: 10.1007/S10803-020-04704-Z.
- [11] S. A. Abdullah, S. A. razak, M. S. B. Yusoff, A. Othman, N. A. Yahaya, and N. Mohamad, "Burnout and Stressor-Related Factors among Caretaker of Children with Chronic Neurological Illness," *Malaysian Journal of Paediatrics and Child Health*, vol. 27, no. 2, pp. 7–18, Aug. 2021, doi: 10.51407/mjpch.v27i2.140.
- [12] B. K. Matin *et al.*, "Contributing factors to healthcare costs in individuals with autism spectrum disorder: a systematic review," *BMC Health Serv Res*, vol. 22, no. 1, pp. 1–20, Dec. 2022, doi: 10.1186/S12913-022-07932-4
- [13] J. Qu *et al.*, "Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis," *Front Pediatr*, vol. 10, p. 897398, May 2022, doi: 10.3389/FPED.2022.897398.
- [14] Y. Wu *et al.*, "Can pluripotent/multipotent stem cells reverse Parkinson's disease progression?," *Front Neurosci*, vol. 18, p. 1210447, Jan. 2024, doi: 10.3389/FNINS.2024.1210447.
- [15] J. Gordon, G. Lockard, M. Monsour, A. Alayli, H. Choudhary, and C. V. Borlongan, "Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy," *International Journal of Molecular Sciences 2022, Vol. 23, Page 10138*, vol. 23, no. 17, p. 10138, Sep. 2022, doi: 10.3390/IJMS231710138.
- [16] L. K. Mitchell and P. S. W. Davies, "Pre- and probiotics in the management of children with autism and gut issues: a review of the current evidence," *European Journal of Clinical Nutrition 2021 76:7*, vol. 76, no. 7, pp. 913–921, Oct. 2021, doi: 10.1038/s41430-021-01027-9.
- [17] T. C. Mohammadi, K. Jazi, A. Bolouriyan, and A. Soleymanitabar, "Stem cells in treatment of crohn's disease: Recent advances and future directions," *Transpl Immunol*, vol. 80, p. 101903, Oct. 2023, doi: 10.1016/J.TRIM.2023.101903.
- [18] K. Bahrehbar, M. R. Valojerdi, F. Esfandiari, R. Fathi, S. N. Hassani, and H. Baharvand, "Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure," *World J Stem Cells*, vol. 12, no. 8, pp. 857–878, Aug. 2020, doi: 10.4252/WJSC.V12.I8.857.
- [19] J. Penney, W. T. Ralvenius, and L. H. Tsai, "Modeling Alzheimer's disease with iPSC-derived brain cells," *Molecular Psychiatry 2019 25:1*, vol. 25, no. 1, pp. 148–167, Aug. 2019, doi: 10.1038/s41380-019-0468-3.
- [20] G. Shroff, "A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells," *Stem Cells Cloning*, vol. 11, pp. 1–11, Feb. 2018, doi: 10.2147/SCCAA.S135415.
- [21] E. Courchesne, V. H. Gazestani, and N. E. Lewis, "Prenatal Origins of ASD: The When, What, and How of ASD Development," *Trends Neurosci*, vol. 43, no. 5, pp. 326–342, May 2020, doi: 10.1016/j.tins.2020.03.005.
- [22] S. A. Keim *et al.*, "Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder," *J Autism Dev Disord*, vol. 52, no. 12, pp. 5342–5355, Dec. 2022, doi: 10.1007/S10803-021-05396-9.
- [23] K. Shigematsu, N. Komori, K. Tahara, and H. Yamagishi, "Repeated infusion of autologous adipose tissue-derived stem cells for Parkinson's disease," *Acta Neurol Scand*, vol. 145, no. 1, pp. 119–122, Jan. 2022, doi: 10.1111/ANE.13547.
- [24] E. Augulia and L. Fusar-Poli, "Still a Long Way to Go. Editorial for the Special Issue 'Understanding Autism Spectrum Disorder,'" *Brain Sciences 2021, Vol. 11, Page 1062*, vol. 11, no. 8, p. 1062, Aug. 2021, doi: 10.3390/BRAINS11081062.
- [25] CDC, "Data & Statistics on Autism Spectrum Disorder | CDC." Accessed: Apr. 26, 2024. [Online]. Available: <https://www.cdc.gov/ncbddd/autism/data.html>
- [26] R. Choueiri, W. T. Garrison, and V. Tokatli, "Early Identification of Autism Spectrum Disorder (ASD): Strategies for Use in Local Communities," *Indian J Pediatr*, vol. 90, no. 4, pp. 377–386, Apr. 2023, doi: 10.1007/S12098-022-04172-6.

- [27] N. Vijjaratnam, T. Simuni, O. Bandmann, H. R. Morris, and T. Foltynie, "Progress towards therapies for disease modification in Parkinson's disease," *Lancet Neurol*, vol. 20, no. 7, pp. 559–572, Jul. 2021, doi: 10.1016/S1474-4422(21)00061-2.
- [28] Y. Yang, Y. Peng, Y. Li, T. Shi, Y. Luan, and C. Yin, "Role of stem cell derivatives in inflammatory diseases," *Front Immunol*, vol. 14, p. 1153901, Mar. 2023, doi: 10.3389/FIMMU.2023.1153901.
- [29] Y. Xu and Q. Wu, "Prevalence trend and disparities in rheumatoid arthritis among us adults, 2005–2018," *J Clin Med*, vol. 10, no. 15, p. 3289, Aug. 2021, doi: 10.3390/JCM10153289
- [30] K. Cushing and P. D. R. Higgins, "Management of Crohn Disease: A Review," *JAMA*, vol. 325, no. 1, pp. 69–80, Jan. 2021, doi: 10.1001/JAMA.2020.18936.
- [31] M. E. Burczynski *et al.*, "Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells," *Journal of Molecular Diagnostics*, vol. 8, no. 1, pp. 51–61, Feb. 2006, doi: 10.2353/jmoldx.2006.050079.

**Publish your books with AIJR publisher-**

- Publish with ISBN and DOI.
- Publish Thesis/Dissertation as Monograph.
- Publish Book Monograph.
- Publish Edited Volume/ Book.
- Publish Conference Proceedings
- Retain full copyright of your books.

Submit your manuscript at [books.aijr.org](https://books.aijr.org)

**Publish your research article in AIJR journals-**

- Online Submission and Tracking
- Peer-Reviewed
- Rapid decision
- Immediate Publication after acceptance
- Articles freely available online
- Retain full copyright of your article.

Submit your article at [journals.aijr.org](https://journals.aijr.org)